NCT01307449

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

Systems Biology of 23 Valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: 25 Years – 89 Years
• Healthy volunteers: Accepted

Summary

Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vaccine development particularly for the geriatric population. In this trial, the investigators will study the immunologic differences of two FDA approved licensed pneumococcal vaccines between a younger and an older group. Twenty two healthy volunteers between the age of 25-40 and sixty six healthy volunteers between the ages of 60-89 will be enrolled in the study. Each participant in the study will be given one pneumococcal shot. Blood work will be obtained prior to vaccination, one day, three days, seven days, fourteen days, as well as one month and six months after vaccination. Throughout the duration of the study, the participants will be monitored for safety.

Detailed description

RATIONALE: PCV13 \[13-valent pneumococcal conjugate vaccine (Prevnar®13)\] induces better functional immune responses when compared to PPV23 \[23-valent pneumococcal polysaccharide vaccine (Pneumovax®23)\] in older naïve adults. We hypothesize that this is due to intrinsic defects in innate responses that could explain the poor immunogenicity of PPV23 when compared to PCV13. Therefore, we propose to extensively study innate and adaptive immune responses generated after administration of either pneumococcal polysaccharide or conjugate vaccines in older adults. STUDY DESIGN: Single center, open label study in which adult healthy volunteers will be vaccinated with either PPV23 or PCV13. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immune responses. Even though PPV23 and PCV13 are considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 . Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Also volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination. Volunteers are also asked to report local and systemic AEs developing the day of a blood draw.

Conditions

• Pneumococcal Infection

Interventions

Type	Name	Description
BIOLOGICAL	PNEUMOVAX	1 dose of PNEUMOVAX
BIOLOGICAL	Prevnar	1 dose of Prevnar

Timeline

• Start date: 2014-04-01
• Primary completion: 2017-07-01
• Completion: 2017-07-01
• First posted: 2011-03-03
• Last updated: 2018-10-02
• Results posted: 2018-10-02

Locations

2 sites across 1 country: United States